An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma.
Paula Rodríguez OteroKevin TowleShannon CopeClyde CaisipFaith E DaviesMichel DelforgeKatja WeiselThomas S MarshallKorinna KarampampaDieter AyersAli MojebiJulia BravermanJames FarrellDevender DhandaPublished in: Leukemia & lymphoma (2023)